Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. In two independent patient cohorts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), mirrored by concomitant changes in circulating donor T cells. Likewise, we documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leukemia cells, due to downregulation of the HLA class II regulator CIITA. We show that loss of HLA class II expression and upregulation of inhibitory checkpoint molecules represent alternative modalities to abolish AML recognition from donor-derived T cells, and can be counteracted by interferon-γ or checkpoint blockade, respectively. Our results demonstrate that the deregulation of pathways involved in T cell-mediated allorecognition is a distinctive feature and driver of AML relapses after allo-HCT, which can be rapidly translated into personalized therapies.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation / C. Toffalori, L. Zito, V. Gambacorta, M. Riba, G. Oliveira, G. Bucci, M. Barcella, O. Spinelli, R. Greco, L. Crucitti, N. Cieri, M. Noviello, F. Manfredi, E. Montaldo, R. Ostuni, M.M. Naldini, B. Gentner, M. Waterhouse, R. Zeiser, J. Finke, M. Hanoun, D.W. Beelen, I. Gojo, L. Luznik, M. Onozawa, T. Teshima, R. Devillier, D. Blaise, C.J.M. Halkes, M. Griffioen, M.G. Carrabba, M. Bernardi, J. Peccatori, C. Barlassina, E. Stupka, D. Lazarevic, G. Tonon, A. Rambaldi, D. Cittaro, C. Bonini, K. Fleischhauer, F. Ciceri, L. Vago. - In: NATURE MEDICINE. - ISSN 1078-8956. - 25:4(2019 Apr), pp. 603-611. [10.1038/s41591-019-0400-z]

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

M. Barcella;L. Crucitti;N. Cieri;M.G. Carrabba;C. Barlassina;A. Rambaldi;
2019-04

Abstract

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. In two independent patient cohorts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), mirrored by concomitant changes in circulating donor T cells. Likewise, we documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leukemia cells, due to downregulation of the HLA class II regulator CIITA. We show that loss of HLA class II expression and upregulation of inhibitory checkpoint molecules represent alternative modalities to abolish AML recognition from donor-derived T cells, and can be counteracted by interferon-γ or checkpoint blockade, respectively. Our results demonstrate that the deregulation of pathways involved in T cell-mediated allorecognition is a distinctive feature and driver of AML relapses after allo-HCT, which can be rapidly translated into personalized therapies.
Settore MED/15 - Malattie del Sangue
25-mar-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
s41591-019-0400-z.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 8.38 MB
Formato Adobe PDF
8.38 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/636509
Citazioni
  • ???jsp.display-item.citation.pmc??? 86
  • Scopus 137
  • ???jsp.display-item.citation.isi??? 151
social impact